| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CAR; LEU5; RFP2; DLEU5; RNF77 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human TRIM13 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TRIM13抗体的3篇参考文献示例(注：内容为虚构，仅用于示例格式)：
1. **"TRIM13 regulates apoptosis via ubiquitination in B-cell malignancies"**
- **作者**: Smith A, et al.
- **摘要**: 本研究通过Western blot和免疫共沉淀实验，利用TRIM13抗体揭示了其在B细胞淋巴瘤中通过泛素化调控促凋亡蛋白的机制，表明TRIM13可能作为肿瘤抑制因子发挥作用。
2. **"TRIM13 antibody-based detection of protein expression in neurodegenerative disorders"**
- **作者**: Lee J, et al.
- **摘要**: 通过免疫组化技术结合TRIM13抗体，发现TRIM13在阿尔茨海默病患者脑组织中表达显著下调，提示其可能与神经退行性病变中的蛋白稳态失衡相关。
3. **"Characterization of TRIM13 in endoplasmic reticulum stress using specific antibodies"**
- **作者**: Chen R, et al.
- **摘要**: 采用TRIM13抗体进行免疫荧光染色，证实TRIM13定位于内质网，并在内质网应激条件下通过调控IRE1α通路影响细胞存活。
(注：以上文献及作者名为示例性虚构，实际引用需查询真实数据库如PubMed。)
**Background of TRIM13 Antibody**
TRIM13 (Tripartite Motif-containing protein 13) is a member of the TRIM family, characterized by conserved RING, B-box, and coiled-coil domains. It localizes primarily to the endoplasmic reticulum (ER) and plays roles in ER-associated degradation (ERAD), ubiquitination, apoptosis, and immune regulation. TRIM13 functions as an E3 ubiquitin ligase, mediating protein ubiquitination to regulate cellular processes like protein quality control and stress responses. Its involvement in pathways such as NF-κB signaling and p53-mediated apoptosis highlights its dual role in tumor suppression and oncogenesis, depending on cellular context.
TRIM13 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological conditions. These antibodies enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Research using TRIM13 antibodies has linked its dysregulation to cancers (e.g., multiple myeloma, leukemia), neurodegenerative diseases, and viral infections, underscoring its therapeutic potential. Additionally, studies explore TRIM13's interaction with viral proteins and its role in modulating autophagy and ER stress.
Validated TRIM13 antibodies are critical for ensuring specificity, particularly given structural similarities among TRIM family members. Ongoing research aims to clarify its mechanistic roles and explore TRIM13 as a biomarker or therapeutic target in disease.
×
